Mepolizumab (Nucala)
The objective of this review is to evaluate the beneficial and harmful effects of mepolizumab 100 mg subcutaneous (SC) for the maintenance treatment of adult patients with severe eosinophilic asthma (SEA) whose symptoms are inadequately controlled with high-dose inhaled corticosteroid(s)(ICS) and on...
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2016, 2016 Nov
|
Series: | Common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The objective of this review is to evaluate the beneficial and harmful effects of mepolizumab 100 mg subcutaneous (SC) for the maintenance treatment of adult patients with severe eosinophilic asthma (SEA) whose symptoms are inadequately controlled with high-dose inhaled corticosteroid(s)(ICS) and one or more additional asthma controllers |
---|---|
Physical Description: | 1 online resource illlustration |